Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU Platform Trial in Dominantly Inherited Alzheimer's Disease
NCT01760005Phase 3Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2012
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of gantenerumab, solanezumab, etalanetug in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Started Dec 2012; status: active, not recruiting.
02
Drugs
gantenerumabsolanezumabetalanetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01760005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01760005.